Petros Grivas: Stellar presentation by Brian Rini on KN426 trial
Petros Grivas shared a post by Tian Zhang, on X:
“Stellar presentation by Brian Rini on biomarkers from practice changing from KN426 trial! Important to see biomarker work from positive trials! ”
Quoting Tian Zhang‘s post:
“Brian Rini with biomarker analysis of keynote426 trial — T cell inflamed tends to favor axi-pembro and angiogenesis signature seems to favor sunitinib.”
Source: Petros Grivas/X and Tian Zhang/X
Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
Dr. Tian Zhang, an Associate Professor at UT Southwestern Medical Center, specializes in diagnosing and treating genitourinary cancers, including kidney, prostate, bladder, and testicular cancers. She focuses on clinical trials and translational research to develop new therapies and evaluate biomarkers for these malignancies. Dr. Zhang is a member of ASCO, AACR, and ESMO.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023